- Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers - IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients with recurrent glioblastoma - Results further support development of
-Expanding Controlled IL-12 platform to explore additional tumor types -Cash runway extended to 2Q 2019 with changes to Controlled IL-12 development plans -ASCO poster to detail IL-12 data in breast cancer, glioblastoma, highlight potential for combination with checkpoint inhibitors
BOSTON , May 02, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, May 10 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended
BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and
BOSTON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company that would be the cause of the recent volatility and decline in
- Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO ® (nivolumab) - - Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology targets - BOSTON, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc.
BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 10 a.m. PST.
— Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty -modified CD19-specific CAR + T cells — — Point-of-care CD19-specific CAR + T cells co-expressing mbIL15 with control switch show sustained persistence, anti-tumor effect in preclinical
